Novo Nordisk lands back in Sanders' crosshairs, this time over steep costs of Ozempic and Wegovy
Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co., and Johnson & Johnson about the high costs of their drugs, Sen. Bernie Sanders, I-Vermont, is taking Novo Nordisk to task for allegedly turning its blockbuster GLP-1s, …